TEL AVIV, Israel, Jan. 4, 2022 /PRNewswire/ -- Chemomab
Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage
biotechnology company focused on the discovery and development of
innovative therapeutics for fibrotic and inflammatory diseases with
high unmet need, today named Jack
Lawler Vice President of Global Clinical Development
Operations. Mr. Lawler, who is based in the U.S., brings more than
22 years of clinical drug development experience, including
contributing to the development of eight approved pharmaceutical
products across a variety of therapeutic indications.
Separately, Chemomab announced that it has expanded its
scientific and business facilities in Tel
Aviv to better accommodate its expected growth.
"We are delighted to welcome Jack to Chemomab, with his more
than two decades of experience in clinical development planning,
operations and management, spanning pre-IND activities through CMC
and regulatory," said Dale Pfost,
PhD, Chief Executive Officer of Chemomab. "We look forward to his
contributions as we build out our U.S.-based clinical development
team that complements our existing clinical expertise in
Israel."
Prior to joining Chemomab, Mr. Lawler served on the senior
leadership team at Goldfinch Bio as Vice President, Clinical
Operations and Data Management. Earlier, Mr. Lawler held a series
of drug development positions of increasing responsibility at
biopharmaceutical firms including Cephalon (acquired by Teva),
Trevena, Viropharma (acquired by Shire), Botanix and Egalet. He
participated in the successful development of numerous
pharmaceutical products, including Cinqair®,
Provigil® and Nuvigil®, among others. Earlier
in his career, Mr. Lawler worked in emergency and transplant
medicine. He earned a Bachelor of Science degree summa cum laude
from Rosemont
College.
Dr. Pfost continued, "While augmenting our human capital in the
U.S., we are also strengthening the company's core scientific
enterprise with our move to a larger facility with advanced
technology designed to better enable our Israel-based R&D and business
operations."
Chemomab's new office and research laboratory facilities located
in the Atidim Park in Tel Aviv,
Israel were developed and built expressly for Chemomab's
current and future anticipated research needs. They are equipped
with cutting-edge technology that will help the company continue to
develop its lead clinical programs as well as new projects going
forward.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing
on the discovery and development of innovative therapeutics for
fibrotic and inflammatory diseases with high unmet need. Based on
the unique and pivotal role of the soluble protein CCL24 in
promoting fibrosis and inflammation, Chemomab developed CM-101, a
monoclonal antibody designed to bind and block CCL24 activity.
CM-101 has demonstrated the potential to treat multiple severe and
life-threatening fibrotic and inflammatory diseases. It is
currently in two Phase 2 safety and efficacy trials—one in patients
with primary sclerosing cholangitis and the second in patients with
liver fibrosis, with a third Phase 2 trial in systemic sclerosis
expected to begin early in 2022.
For more information on Chemomab, visit chemomab.com.
Forward Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act. These
forward-looking statements include, among other things, statements
regarding the clinical development pathway for CM-101; the future
operations of Chemomab and its ability to successfully initiate and
complete clinical trials and achieve regulatory milestones; the
nature, strategy and focus of Chemomab; the development and
commercial potential and potential benefits of any product
candidates of Chemomab; and that the product candidates have the
potential to address high unmet needs of patients with serious
fibrosis-related diseases and conditions. Any statements contained
in this communication that are not statements of historical fact
may be deemed to be forward-looking statements. These
forward-looking statements are based upon Chemomab's current
expectations. Forward-looking statements involve risks and
uncertainties. Because such statements deal with future events and
are based on Chemomab's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of Chemomab could differ materially from those
described in or implied by the statements in this presentation,
including: the uncertain and time-consuming regulatory approval
process; risks related to Chemomab's ability to correctly manage
its operating expenses and its expenses; Chemomab's plans to
develop and commercialize its product candidates, focusing on
CM-101; the timing of initiation of Chemomab's planned clinical
trials; the timing of the availability of data from Chemomab's
clinical trials; the timing of any planned investigational new drug
application or new drug application; Chemomab's plans to research,
develop and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of Chemomab's product candidates; Chemomab's
commercialization, marketing and manufacturing capabilities and
strategy; Chemomab's ability to protect its intellectual property
position; and the requirement for additional capital to continue to
advance these product candidates, which may not be available on
favorable terms or at all. Additional risks and uncertainties
relating to Chemomab's and its business can be found under the
caption "Risk Factors" and elsewhere in Chemomab's filings and
reports with the SEC. Chemomab expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Chemomab's expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Contacts:
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations, Strategic Communications
Phone: +1-917-355-9234
barbara@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-names-jack-lawler-vice-president-of-global-clinical-development-operations-301453423.html
SOURCE ChemomAb Ltd.